KDM1A and breast carcinoma: It has been reported to inhibit also LSD1 (Culhane et al., 2010), and entered clinical trials in combination with Abraxane, a nano formulation of Paclitaxel bound to albumin, for the treatment of metastatic or advanced breast cancer (Table 1).